SLA Pharma

SLA Pharma is a privately held, clinical-stage biotech company headquartered in Zug, Switzerland, founded in 1999. It operates with a pure-play focus on gastroenterology, developing small molecule therapies through a strategy of drug repurposing for under-treated GI conditions. The company leverages deep expertise in GI clinical development and partners with global researchers and clinicians to advance its pipeline. Its business model is centered on therapeutic development, and it is currently in a pre-revenue or early-revenue stage as it progresses its clinical programs.

Drug repurposing strategy focused on identifying known chemical entities for new applications in gastrointestinal disorders, leveraging deep GI-specific clinical and regulatory expertise.

SLA Pharma competes with both large pharmaceutical companies with GI divisions (e.g., AbbVie, Takeda, Pfizer) and numerous small-to-mid-size biotechs focused on specific GI conditions. Its differentiation lies in its pure-play GI focus, repurposing expertise, and deep clinical development experience specifically in gastroenterology.